Targeted Fat Loss Results & Timeline
AOD-9604 is a modified fragment of human growth hormone that selectively targets fat metabolism without affecting IGF-1 or lean muscle mass. Research documents meaningful reductions in visceral and subcutaneous fat over 12–24 weeks.
Source: Metabolic Pharmaceuticals Phase II Clinical Trials | Duration: 12–24 weeks | Individual results vary.
Important: Results shown are from clinical trials and represent averages. Individual results vary significantly based on dose, diet, exercise, metabolic health, and adherence. This page is for informational purposes only. Consult a qualified healthcare professional before use.
AOD-9604 begins binding to beta-3 adrenergic receptors in adipose tissue. No visible changes are expected at this stage. Some subjects report mild injection site reactions that resolve within days.
Beta-3 adrenergic receptor activation increases the rate of lipolysis (fat breakdown) in adipose tissue. Subtle reductions in bloating and water retention may be noticed. Body weight changes are minimal at this stage.
First measurable reductions in body fat percentage are typically documented. Waist circumference measurements begin to decrease. Subjects in clinical trials reported improved energy levels during this period, likely secondary to improved fat oxidation.
Continued fat loss with preservation of lean muscle mass. Visceral fat (abdominal) reduction becomes more pronounced. Body composition scans (DEXA) show meaningful reductions in fat mass without corresponding lean mass loss — a key differentiator from caloric restriction alone.
Phase II clinical trials documented average fat mass reductions of approximately 3.5 kg at 24 weeks. Subjects with higher baseline body fat percentages tended to show larger absolute reductions. Lean mass remained stable throughout, confirming AOD-9604's selective mechanism.
AOD-9604 is a synthetic peptide corresponding to amino acids 177–191 of human growth hormone (hGH), with an additional tyrosine residue at the N-terminus to improve stability. This fragment contains the region of hGH responsible for its lipolytic (fat-burning) activity, while lacking the domains responsible for IGF-1 stimulation and anabolic effects.
The peptide exerts its effects through two complementary mechanisms: (1) stimulation of lipolysis via beta-3 adrenergic receptor activation in adipose tissue, which increases the breakdown of stored triglycerides into free fatty acids; and (2) inhibition of lipogenesis, the process by which carbohydrates are converted to fat for storage.
Because AOD-9604 does not bind to the GH receptor with sufficient affinity to stimulate IGF-1 production, it avoids the insulin resistance, joint pain, and carpal tunnel syndrome associated with full-length HGH therapy. This selective mechanism makes it a cleaner tool for fat loss research.
| Compound | Mechanism | Fat Loss | Muscle Preservation | IGF-1 Effect |
|---|---|---|---|---|
| AOD-9604 | Beta-3 AR agonism, anti-lipogenesis | Moderate (~3.5 kg/24 wk) | Excellent | None |
| Semaglutide | GLP-1 receptor agonism | High (15–20%) | Moderate (some loss) | None |
| Tirzepatide | GLP-1 + GIP dual agonism | Very High (20–22%) | Moderate | None |
| Sermorelin | GHRH receptor agonism | Mild–Moderate | Excellent | Moderate increase |
| Full HGH | GH receptor agonism | Moderate | Excellent | High increase |
Most research subjects begin noticing fat loss changes between 4–8 weeks. Significant body composition improvements are typically documented at 12–24 weeks of consistent administration.
No. AOD-9604 selectively targets fat tissue by activating beta-3 adrenergic receptors and inhibiting lipogenesis. It does not affect IGF-1 or lean muscle mass, which distinguishes it from full-length HGH.
Semaglutide produces larger absolute weight loss (15–20%) via appetite suppression and GLP-1 receptor activation. AOD-9604 produces more targeted fat reduction without appetite effects, making it a different tool for different research goals.
Yes. AOD-9604 is commonly researched alongside CJC-1295/Ipamorelin for a combined fat loss and body composition protocol. The mechanisms are complementary and non-overlapping.
No. Unlike full-length HGH, AOD-9604 does not affect insulin sensitivity or blood glucose levels. This was confirmed across multiple Phase II clinical trials.
Purgo Labs provides HPLC-verified, third-party tested AOD-9604 for legitimate research purposes. Every batch includes a certificate of analysis.
Shop AOD-9604 at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.